Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Chatzi L, Torrent M, Romieu I, Garcia-Esteban R, Ferrer C, Vioque J, Kogevinas M, Sunyer J. Diet, wheeze, and atopy in school children in Menorca, Spain. Pediatr Allergy Immunol. 2007 Sep;18(6):480-5. doi: 10.1111/j.1399-3038.2007.00596.x
Longfield JN, Townsend TR, Cruess DF, Stephens M, Bishop (Johannes) C, Bolyard C, Hutchinson E. Methicillin-resistant Staphylococcus aureus (MRSA): risk and outcome of colonized vs. infected patients. Infect Control. 1985 Nov;6(11):445-50. doi: 10.1017/S0195941700064791